Cytori Therapeutics Expands Asia Pacific Celution(TM) System Distribution Network

Cytori Therapeutics (NASDAQ:CYTX) (Frankfurt:XMPA) expanded its Asia Pacific distribution network for the Celution™ System in reconstructive surgery. Two additional distributors will cover Korea, through Olympus Digital Networks Korea (ODNK), and China, through Shanghai Cosmo Medical Products Co., Ltd. (SCMP). These groups will guide and support regulatory clearances, oversee product sales and provide physician education and training in their respective territories.

“Asia-Pacific represents an important and growing reconstructive surgery market for Cytori,” said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. “Aligning ourselves with ODNK expands upon, and reflects the growth in, our partnership with Olympus Corporation. In addition, we look forward to benefiting from SCMP’s existing leadership in the reconstructive surgery market in China.”

“We are pleased to be partnered with Cytori for the commercialization of their Celution™ System,” said Il-Seok Bang, president of ODNK. “Regenerative medicine is an emerging field with a tremendous market opportunity in reconstructive surgery, where we believe there will be significant patient demand.”

Cytori’s Celution™ System is an innovative medical device that removes a patient’s own regenerative cells from their adipose (fat) tissue in about an hour. The cells can then be delivered to the same patient at the bedside in the same surgical procedure.

Cytori Therapeutics

Cytori Therapeutics is a global leader in the development and commercialization of regenerative medicine products. The company is developing therapeutic applications for its Celution™ System to enable real-time regenerative cell therapy in conjunction with breast reconstruction surgery, cardiovascular disease, and other unmet medical needs. The Company’s StemSource™ Cell Bank, which is based on Cytori’s innovative Celution™ System, is being commercialized in Japan to hospitals and clinics to enable regenerative cell banking. www.cytoritx.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading “Risk Factors”) in Cytori Therapeutics’ Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.